- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
Views: 48 Author: Unibest Industrial Publish Time: 2024-06-24 Origin: Site
Query Drug：Lenacapavir
Query Time：2024-06-24 11:06:36
*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Source DAILYMED
Source FDASPL
Source DAILYMED
Source FDASPL
Source DAILYMED
Source FDASPL
Source MEDRT
Source DAILYMED
Source FDASPL
Source MEDRT
[Last update] 2024-05-21
Lenacapavir's Innovator is GILEAD SCIENCES INC
The unique dosage forms from the innovator include：1. SOLUTION;SUBCUTANEOUS；2. TABLET;ORAL.
| Index | Route | Brand Name | Labeler | Approval Date | Dosage |
|---|---|---|---|---|---|
| 1 | SOLUTION;SUBCUTANEOUS | SUNLENCA | GILEAD SCIENCES INC | Dec 22, 2022 | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) |
| 2 | TABLET;ORAL | SUNLENCA | GILEAD SCIENCES INC | Dec 22, 2022 | EQ 300MG BASE |
This drug still has 5 effective patents.
| Patent Number | Submission Date | Expiration Date | Drug Substance Patent? | Drug Product Patent? |
|---|---|---|---|---|
| 10654827 | Jan 18, 2023 | Aug 17, 2037 | ||
| 9951043 | Jan 18, 2023 | Feb 28, 2034 | Y | Y |
| 10071985 | Jan 18, 2023 | Aug 17, 2037 | Y | Y |
| 11267799 | Jan 18, 2023 | Aug 16, 2038 | Y | |
| 11944611 | Apr 23, 2024 | Jun 4, 2041 |
The innovator GILEAD SCIENCES INC's portolio contains products with the following 23 API(s)： COBICISTAT, TENOFOVIR ALAFENAMIDE FUMARATE, COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE, SOFOSBUVIR, AMBRISENTAN, EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE, SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR, SOFOSBUVIR; VELPATASVIR, ADEFOVIR DIPIVOXIL, TENOFOVIR DISOPROXIL FUMARATE, ELVITEGRAVIR, EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE, CIDOFOVIR, REMDESIVIR, COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE, LEDIPASVIR; SOFOSBUVIR, EMTRICITABINE, LENACAPAVIR SODIUM, BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE, EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE, IDELALISIB, EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE, AZTREONAM
The above products are related to 57 diseases： HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, HIV Infections, HIV Infections, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, Hepatitis C, Chronic, Hypertension, Pulmonary, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, Hepatitis C, Chronic, Hepatitis C, Chronic, Hepatitis C, Chronic, Hepatitis C, Chronic, Hepatitis B, Chronic, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, HIV Infections, HIV Infections, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, AIDS-Related Opportunistic Infections, Cytomegalovirus Retinitis, Virus Diseases, Coronavirus Infections, HIV Infections, HIV Infections, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, Hepatitis C, Chronic, Hepatitis C, Chronic, HIV Infections, HIV Infections, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, Lymphoma, Non-Hodgkin, Leukemia, Lymphoid, HIV Infections, HIV Infections, Acquired Immunodeficiency Syndrome, Hepatitis B, Chronic, Cellulitis, Respiratory Tract Infections, Sepsis, Endometritis, Pseudomonas Infections, Urinary Tract Infections, Intraabdominal Infections
![CAS No. 2375019-85-3, 2-Pyridinemethanamine, 3-bromo-α-[(3,5-difluorophenyl)methyl]-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-, (αS)-](http://imrorwxhnlprli5q.ldycdn.com/cloud/jpBpqKkrllSRiknpokjlio/2375019-640-640.gif)
![Cas No. 1620056-47-4, Carbamic acid, N-[(1S)-1-(3,6-dibromo-2-pyridinyl)-2-(3,5-difluorophenyl)ethyl]-, 1,1-dimethylethyl ester](http://imrorwxhnlprli5q.ldycdn.com/cloud/jpBpqKkrllSRikiijlnnin/1620056-640-640.gif)
![Cas No. 1620056-83-8, 1H-Cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-1-acetic acid, 5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, (3bS,4aR)-](http://imrorwxhnlprli5q.ldycdn.com/cloud/jmBpqKkrllSRikiijlonin/1620056-640-640.gif)
![Cas No. 2189684-54-4, Carbamic acid,N-[(1S)-1-[3-bromo-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-,1,1-dimethylethyl ester](http://imrorwxhnlprli5q.ldycdn.com/cloud/jjBpqKkrllSRikiijlmnio/2189684-640-640.gif)
